Myeloablative vs reduced intensity T-cell–replete haploidentical transplantation for hematologic malignancy-Reference-Cited by-同舟云学术

Myeloablative vs reduced intensity T-cell–replete haploidentical transplantation for hematologic malignancy

Published:2019-10-03 Issue:19 Volume:3 Page:2836-2844
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Solomon Scott R.¹,St. Martin Andrew²,Shah Nirav N.³,Fatobene Giancarlo⁴^ORCID,Al Malki Monzr M.⁵,Ballen Karen K.⁶,Bashey Asad¹,Bejanyan Nelli⁷,Bolaños Meade Javier⁸,Brunstein Claudio G.⁹,DeFilipp Zachariah¹⁰^ORCID,Champlin Richard E.¹¹^ORCID,Fuchs Ephraim J.⁸,Hamadani Mehdi²^ORCID,Hematti Peiman¹²,Kanakry Christopher G.¹³,McGuirk Joseph P.¹⁴^ORCID,McNiece Ian K.¹⁵,Ciurea Stefan O.¹¹,Pasquini Marcelo C.²,Rocha Vanderson⁴¹⁶,Romee Rizwan¹⁷,Patel Sagar S.¹⁸^ORCID,Vasu Sumithira¹⁹,Waller Edmund K.²⁰^ORCID,Wingard John R.²¹,Zhang Mei-Jie²,Eapen Mary²^ORCID

Affiliation:

1. The Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA;

2. Center for International Blood and Marrow Transplant Research, and

3. Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI;

4. Hospital das Clinicas da Universidade de São Paulo, São Paulo, Brazil;

5. Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA;

6. Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA;

7. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;

8. The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD;

9. University of Minnesota Medical Center, Minneapolis, MN;

10. Winship Cancer Institute, Massachusetts General Hospital, Boston, MA;

11. University of Texas MD Anderson Cancer Center, Houston, TX;

12. Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, University of Wisconsin, Madison, WI;

13. National Cancer Institute, National Institutes of Health, Bethesda, MD;

14. Division of Hematologic Malignancies and Cellular Therapy, University of Kansas Medical Center, Kansas City, KS;

15. CellMED Consulting, Miami, FL;

16. Department of Haematology, University of Oxford, Oxford, United Kingdom;

17. Division of Hematologic Malignancies and Transplantation, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;

18. Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;

19. Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH;

20. Department of Hematology and Medical Oncology, Winship Cancer Institute, Atlanta, GA; and

21. Division of Heamtology & Oncology, Department of Medicine, University of Florida, Gainesville, FL

Abstract

Key Points Disease-free survival is higher with myeloablative regimens for patients in their third to fifth decade. Beyond the fifth decade, low-dose total body irradiation regimens offset mortality associated with transplant procedure.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/19/2836/1223985/advancesadv2019000627.pdf

Reference30 articles.

1. Current use and trends in hematopoietic cell transplantation in the United States;D’Souza;Biol Blood Marrow Transplant,2017

2. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report;Passweg;Bone Marrow Transplant,2017

3. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide;O’Donnell;Biol Blood Marrow Transplant,2002

4. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide;Luznik;Biol Blood Marrow Transplant,2008

5. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation;Bashey;J Clin Oncol,2013

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Cytomegalovirus Reactivation in Children After Allogeneic Hematopoietic Cell Transplantation in 2 Transplant Eras;Transplantation Proceedings;2024-09

2. Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation;American Journal of Hematology;2024-05-23

3. Current status of conditioning regimens in haploidentical hematopoietic cell transplantation;Hematology;2024-03-21

4. How adoptive transfer of components of the donor immune system boosts GvL and prevents GvHD in HLA-haploidentical hematopoietic transplantation for acute leukemia;Bone Marrow Transplantation;2024-01-11

5. Haploidentical Hematopoietic Cell Transplantation;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024